Blood

Vol. 145, Issue 26 Issue 26 2025
18
Articles

Articles in this Issue

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia

Zhen Gao, Hong Pan, Lele Zhang et al. Jun 26, 2025 pp. 3189-3193 10.1182/blood.2025029006

Abstract We found that 8 of 10 patients with aplastic anemia experienced resolution of platelet transfusion refractoriness following daratumumab administration. Notably, 4 responders...

Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma

Matteo Claudio Da Vià, Francesca Lazzaroni, Antonio Matera et al. Jun 26, 2025 pp. 3124-3138 10.1182/blood.2024025643

Abstract Multiple myeloma (MM) is driven by clonal plasma cell (cPC)–intrinsic factors and changes in the tumor microenvironment (TME). To investigate whether residual polyclonal PCs...

Genotype-specific immune responses at the intestinal barrier predispose to colitis in mouse models of chronic granulomatous disease

Emma Darbinian, Kodjovi D. Mlaga, Prabha Chandrasekaran et al. Jun 26, 2025 pp. 3153-3165 10.1182/blood.2024026332

Abstract Chronic granulomatous disease (CGD) is an inborn error of immunity that is caused by defects in any 1 of the 5 subunits (gp91phox, p47phox, p22phox, p67phox, p40phox) that f...

Activated protein C takes a bite out of factor Va

Shekhar Kumar Jun 26, 2025 pp. 3072-3073 10.1182/blood.2025029477

Cryo-EM structure of coagulation factor Va bound to activated protein C

Bassem M. Mohammed, Katherine Basore, Enrico Di Cera Jun 26, 2025 pp. 3166-3177 10.1182/blood.2025028476

Abstract Coagulation factor Va (FVa) is the cofactor component of the prothrombinase complex required for rapid generation of thrombin from prothrombin in the penultimate step of the...

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Juan Carlos Hernández-Boluda, Adrián Mosquera-Orgueira, Luuk Gras et al. Jun 26, 2025 pp. 3139-3152 10.1182/blood.2024027287

Abstract With the incorporation of effective therapies for myelofibrosis (MF), accurately predicting outcomes after allogeneic hematopoietic cell transplantation (allo-HCT) is crucia...

It takes 2 to inflame: microbiota and genotype shape CGD IBD

Rui A. Carvalho, M Margarida Souto-Carneiro Jun 26, 2025 pp. 3069-3072 10.1182/blood.2025029443

Pathogenesis of paroxysmal nocturnal hemoglobinuria

Lucio Luzzatto, Shinji Nakao Jun 26, 2025 pp. 3077-3088 10.1182/blood.2024025975

Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a nonmalignant clonal hematopoietic disorder. There are 2 components to the pathogenesis of PNH: (1) a mutant stem cell and (2)...

When the silence speaks: T-cell dysfunction in myeloma

Mirco J. Friedrich, Marc S. Raab Jun 26, 2025 pp. 3064-3066 10.1182/blood.2025029262

B-lymphoblastic leukemia with <i>KMT2A</i> rearrangement with mature B-cell phenotype and surface λ light-chain restriction

Pratik Q. Deb, Xinmin Zhang Jun 26, 2025 pp. 3194-3194 10.1182/blood.2025029108

A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil

Ibrahim M. Idris, Aminu A. Yusuf, Ismail I. Ismail et al. Jun 26, 2025 pp. 3101-3112 10.1182/blood.2024027898

Abstract Recurrent ischemic priapism is a common complication of sickle cell anemia (SCA) and is associated with devastating physical and psychosocial consequences. All previous tria...

The evolving landscape of hereditary stomatocytosis

Immacolata Andolfo, Achille Iolascon, Roberta Russo Jun 26, 2025 pp. 3089-3100 10.1182/blood.2024024294

Abstract Hereditary stomatocytosis represents a heterogeneous group of inherited erythrocyte membrane defects characterized by hemolytic anemia of variable degree, with alterations i...

More than myeloma: the trouble with “normal” plasma cells

Ross S. Firestone, Francesco Maura Jun 26, 2025 pp. 3066-3067 10.1182/blood.2025028750

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD

Katharina M. Habenicht, Jana Wanzek, Anna Bootz et al. Jun 26, 2025 pp. 3178-3188 10.1182/blood.2024027301

Abstract Chronic graft-versus-host disease (cGVHD) is characterized by dysregulation of the adaptive immune system, including an aberrant B-cell homeostasis after allogeneic hematopo...

Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy

Carolyn Shasha, David R. Glass, Ernest Moelhman et al. Jun 26, 2025 pp. 3113-3123 10.1182/blood.2024025655

Abstract Dysregulation of the bone marrow (BM) niche in multiple myeloma (MM) alters the composition and state of resident immune cells, potentially impeding antitumor immunity. One...

An AI model of transplantation risk for myelofibrosis

Simón Méndez-Ferrer Jun 26, 2025 pp. 3068-3069 10.1182/blood.2025028816

NO (nitric oxide) to priapism with hydroxyurea and tadalafil

Kenneth I. Ataga Jun 26, 2025 pp. 3063-3064 10.1182/blood.2025028905

Microbiota and chronic GVHD: a plasmablast link

Armin Rashidi Jun 26, 2025 pp. 3073-3075 10.1182/blood.2025029521

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page